Key Takeaways:
The arrival of GLP-1 weight loss pills from Novo Nordisk and Eli Lilly may paradoxically accelerate employer insurance coverage cuts rather than expand patient access.
Novo Nordisk introduced its Wegovy tablet for weight loss in January, and Eli Lilly's Foundayo pill began shipping in April. While industry observers hoped oral versions would carry lower price tags, they cost employers roughly the same as injectables — a net price of $569 to $664 per employee monthly after discounts, according to the Institute for Clinical and Economic Review.
"The net prices of these drugs have come down, and I think there will continue to be pressure on them to come down, especially as other manufacturers' drugs get approved," said Jeff Levin-Scherz, population health leader at WTW. "That will hopefully continue to lower prices."
A Business Group on Health survey found 87% of large employers expect the availability of oral medications to increase demand for GLP-1s, while only 9% predict a price drop. In NFP's annual employer survey, 51% of companies cited GLP-1s as the top driver of rising prescription drug costs. "Employers say the rise in pharmacy costs is unsustainable," said Nick Conway, president of Rx Solutions at NFP.
The cost crunch is already reshaping coverage decisions. Among employers with 500 or more workers, 6% dropped GLP-1 weight-loss coverage in 2026, and 5% are planning to drop or actively considering doing so for 2027, according to Mercer. The Business Group on Health found that 10% of companies covering GLP-1s for weight management are unlikely to continue in 2027 for cost reasons, said Magda Rusinowski, vice president of the non-profit.
Some employers are tightening eligibility requirements. While many plans historically required a body mass index of 30 or higher — or 27 with a weight-related condition — some now demand a BMI of 35 or above to qualify, said Eileen Pincay, national pharmacy practice leader at Segal. Others are restricting coverage to diabetic patients only or imposing stricter behavioral management requirements.
Employers explore alternative access models
Some companies are bypassing traditional pharmacy benefits altogether. Employers can reimburse workers through health reimbursement arrangements or provide access through third-party weight management programs. Eli Lilly has relationships with more than 15 independent program administrators including 9amHealth, GoodRx and Goodpath to offer tailored obesity coverage. Novo Nordisk offers a similar employer program.
Oral GLP-1 medications are available direct-to-consumers with cash prices starting at $149 per month for the lowest doses, compared with $199 to $299 for injectable starting doses. However, patients do not remain on initial doses, so actual per-month costs rise.
A major factor keeping prices elevated is that only two pharmaceutical companies — Novo Nordisk and Eli Lilly — currently produce these drugs. That is expected to change as competitors enter the market, though likely not for at least a year, said Ben Barner, clinical pharmacy leader at Brown & Brown.
On the public side, Medicare will launch a pilot program July 1 offering certain GLP-1 medications for obesity at a flat $50 monthly copay, the first time the program has covered weight-loss drugs. The pilot runs through Dec. 31, 2027.
For employers, the calculus remains difficult. They face high upfront costs for drugs that patients often discontinue within a year, negating long-term health benefits. "Employers are concerned about spending so much money without knowing employees are committed and able to reap the long-term health benefits," Barner said.
The coverage pullback signals a structural headwind for Novo Nordisk and Eli Lilly's revenue growth projections. Investors will watch the Medicare pilot's enrollment data and any competitor drug approvals in 2027 as the next catalysts for pricing and access dynamics.
This article is for informational purposes only and does not constitute investment advice.
